Evidence map›Paper›PMID 23959876›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2013

Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4.

Xiaoban Xin, Murilo Rodrigues, Mahaa Umapathi, Fabiana Kashiwabuchi, Tao Ma, Savalan Babapoor-Farrokhran, Shuang Wang, Jiadi Hu, Imran Bhutto, Derek S Welsbie and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 160 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and neck cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Molecular stress and neurovascular injury in the diabetic retina.The Journal of clinical investigation · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Early-stage diabetic retinopathy: gut-metabolic triggers, immune-neurodegeneration, and interventions.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Xiaoban XinWilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Murilo Rodrigues
Mahaa Umapathi
Fabiana Kashiwabuchi
Tao Ma
Savalan Babapoor-Farrokhran
Shuang Wang
Jiadi Hu
Imran Bhutto
Derek S Welsbie
Elia J Duh
James T Handa
Charles G Eberhart
Gerard Lutty
Gregg L Semenza
Silvia Montaner
Akrit Sodhi
Johns Hopkins University · USUniversity of Maryland, Baltimore · USJohns Hopkins Medicine · USRadiation Oncology Associates · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
Vasculogenesis and hyperoxia in the developing retina.R01EY009357 · NEI · JOHNS HOPKINS UNIVERSITY · PI LUTTY, GERARD ANTHONY · 1993 to 2014
$5.3M
HIF dysregulation as a novel genetic model to study retinal neovascular disease.K08EY021189 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2011 to 2015
$898k
NEI NIH HHS EY001765NEI NIH HHS K08 EY021189NEI NIH HHS K08- EY021189NEI NIH HHS P30 EY001765NEI NIH HHS R01 EY009357
6 · The paper itself

Abstract

Vision loss from ischemic retinopathies commonly results from the accumulation of fluid in the inner retina [macular edema (ME)]. Although the precise events that lead to the development of ME remain under debate, growing evidence supports a role for an ischemia-induced hyperpermeability state regulated, in part, by VEGF. Monthly treatment with anti-VEGF therapies is effective for the treatment of ME but results in a major improvement in vision in a minority of patients, underscoring the need to identify additional therapeutic targets. Using the oxygen-induced retinopathy mouse model for ischemic retinopathy, we provide evidence showing that hypoxic Müller cells promote vascular permeability by stabilizing hypoxia-inducible factor-1α (HIF-1α) and secreting angiogenic cytokines. Blocking HIF-1α translation with digoxin inhibits the promotion of endothelial cell permeability in vitro and retinal edema in vivo. Interestingly, Müller cells require HIF--but not VEGF--to promote vascular permeability, suggesting that other HIF-dependent factors may contribute to the development of ME. Using gene expression analysis, we identify angiopoietin-like 4 (ANGPTL4) as a cytokine up-regulated by HIF-1 in hypoxic Müller cells in vitro and the ischemic inner retina in vivo. ANGPTL4 is critical and sufficient to promote vessel permeability by hypoxic Müller cells. Immunohistochemical analysis of retinal tissue from patients with diabetic eye disease shows that HIF-1α and ANGPTL4 localize to ischemic Müller cells. Our results suggest that ANGPTL4 may play an important role in promoting vessel permeability in ischemic retinopathies and could be an important target for the treatment of ME.

Indexed as

Capillary PermeabilityAngiopoietin-Like Protein 4AngiopoietinsAnimalsBlotting, WesternCell HypoxiaCells, CulturedDiabetic RetinopathyFemaleGene Expression ProfilingHumansHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryIschemiaMiceMice, Inbred C57BLAngiopoietin-Like Protein 4AngiopoietinsAngptl4 protein, mouseHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth Factor Aangiogenesisdiabetesretinal vein occlusiontranscription factor

Identifiers

PMID23959876
PMCPMC3767527
OpenAlexW2088059932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.